DBV Technologies S.A. (EPA:DBV)
3.565
+0.035 (0.99%)
At close: Mar 13, 2026
DBV Technologies Revenue
Revenue (ttm)
$4.69M
Revenue Growth
-56.04%
P/S Ratio
211.52
Revenue / Employee
$40.08K
Employees
117
Market Cap
991.91M EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | 16.71M | 2.42M | 16.90% |
| Dec 31, 2017 | 14.29M | 4.73M | 49.50% |
| Dec 31, 2016 | 9.56M | 2.86M | 42.76% |
| Dec 31, 2015 | 6.70M | 933.42K | 16.20% |
| Dec 31, 2014 | 5.76M | 500.37K | 9.51% |
| Dec 31, 2013 | 5.26M | 1.60M | 43.65% |
| Dec 31, 2012 | 3.66M | 1.24M | 51.01% |
| Dec 31, 2011 | 2.43M | 143.69K | 6.30% |
| Dec 31, 2010 | 2.28M | 734.19K | 47.44% |
| Dec 31, 2009 | 1.55M | 93.10K | 6.40% |
| Dec 31, 2008 | 1.45M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Valneva SE | 179.91M |
| Cellectis | 70.36M |
| Genfit | 45.13M |
| MedinCell | 32.44M |
| Inventiva | 16.97M |
| Innate Pharma | 12.64M |
| Nanobiotix | 10.16M |
| Transgene | 7.58M |
DBV Technologies News
- 10 days ago - DBV Technologies S.A.: DBV Technologies to Participate in Upcoming March Investor Conferences - Finanz Nachrichten
- 10 days ago - DBV Technologies to Participate in Upcoming March Investor Conferences - GlobeNewsWire
- 11 days ago - DBV Technologies S.A.: Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of February 28, 2026 - Finanz Nachrichten
- 12 days ago - DBV Technologies Peanut Patch Meets Primary Endpoint In Phase 3 VITESSE Study - Nasdaq
- 13 days ago - DBVT Shares Promising Phase 3 Trial Results for Viaskin Peanut - GuruFocus
- 14 days ago - DBV Technologies S.A.: DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting - Finanz Nachrichten
- 14 days ago - DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting - GlobeNewsWire
- 4 weeks ago - DBV Technologies To Present Additional VITESSE Phase 3 Data In Peanut-Allergic Children - Nasdaq